Chemical Namecobimetinib
Dosage FormTablet (oral; 20 mg)
Drug ClassKinase inhibitors
CompanyGenentech Inc.
Approval Year2015


  • To be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation)
Last updated on 10/30/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Cotellic (cobimetinib) Prescribing Information 2018Genentech USA, Inc., South San Francisco, CA
Document TitleYearSource
Systemic therapy for melanoma: ASCO Guideline. 2020Journal of Clinical Oncology